FindTrial
Sign In

Effect of Topical Tacrolimus as an Add on therapy to Direct Visual Internal Urethrotomy(DVIU) Compared To DVIU Alone In Preventing Recurrence in patients of Short-Segment Anterior Urethral Stricture Disease

Effect of Topical Tacrolimus as an Adjuvant to Direct Visual Internal Urethrotomy(DVIU) Compared To DVIU Alone In Preventing Recurrence in patients of Short-Segment Anterior Urethral Stricture Disease A Single-Blinded Randomized Controlled Trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/109402
Enrollment
92
Registered
2026-04-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N359- Urethral stricture, unspecified

Interventions

Intervention1: Application of Tacrolimus ointment 0.1 percent post surgery (Direct Visual Internal Urethrotomy) procedure.: Post surgical procedure(DVIU) patients will do self calibration with per ur

Sponsors

All India Institute Of Medical Sciences Raebareli
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients with anterior urethral stricture disease upto 2 cm in length.

Exclusion criteria

Exclusion criteria: 1.All strictures more than 2 cm in length on Retrograde Urethrography. 2.Patients with benign prostatic hyperplasia symptoms ,posterior urethral stricture disease, altered renal function tests. 3.Patients with previous intervention for urethral stricture disease.

Design outcomes

Primary

MeasureTime frame
Prevention of recurrence Of urethral stricture diseaseTimepoint: At 6 weeks all patients will undergo outcome assessment with AUA symptom score Uroflowmetry(UFM) Ultrasonography for post-void residual urine( USG KUB WITH PVR) Retrograde urethrography( RGU) Urethrocystoscopy Patients will subsequently be followed at 6, 12, and 18 months using AUA symptom score, uroflowmetry, and RGU—

Secondary

MeasureTime frame
Prevention of recurrence will be further evaluated in terms of 1.Etiology of stricture. 2.Site of stricture. 3.Length of stricture. Timepoint: 6 months 12 months 18 months—

Countries

India

Contacts

Public ContactAmit Kumar Mishra

AIIMS Raebareli

amit.mishra.uro@gmail.com9161237733

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026